Overview

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

Status:
Terminated

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

This pilot phase II trial study evaluates the usefulness of the ferumoxytol steady state magnetic resonance imaging (MRI) technique for response assessment after pembrolizumab and radiation therapy in non-small cell lung cancer that has spread to the brain (brain metastases). The interactions of monoclonal antibodies such as pembrolizumab, and the body's immune system may result in an anti-tumor effect. However, it may also increase inflammation around the tumor which cannot be differentiated from true tumor growth on standard MRI. This study evaluates ferumoxytol as an MRI contrast agent to differentiate this treatment related inflammation from true tumor growth.

Phase:

Phase 2

Details

Lead Sponsor:

OHSU Knight Cancer Institute

Collaborators:

Merck Sharp & Dohme Corp.
National Cancer Institute (NCI)
Oregon Health and Science University

Treatments:

Ferrosoferric Oxide
Pembrolizumab